Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody October 3, 2022
DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO September 27, 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies September 23, 2022
New CRISPR Startup, Drawing Big-Name Backers, Seeks to Fix Diseases Caused by Large DNA Errors September 20, 2022
Going Beyond Protein Degradation, a New Broad Startup Kicks into Gear to Fix Protein Functionality September 8, 2022
